Cancer Commons
- Company typePrivate
- Founded2011
- HeadquartersPalo Alto, United States
- Headcount11–50
- GTM typeB2C
- OfferingServices
Cancer Commons firmographics
Firmographics- Name
- Cancer Commons
- Legal name
- Cancer Commons
- Website
- https://cancercommons.org
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Cancer Commons industry classification
Industry- Product category
- Oncology Patient Navigation Services
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Misc Health & Allied Services, Nec (8090), Services-Health Services (8000)
- akta.pro primary industry
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)
- akta.pro secondary industries
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Clinical Document & Data Exchange (C-CDA, CCD, Direct Messaging) (HLACABAI), Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD)
Keywords
Where Cancer Commons is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cancer Commons business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Philanthropic Donations: Cancer Commons is a 501(c)(3) nonprofit that provides all services free to patients, funded entirely through charitable donations. The organization states that every donation of $2,000 or more offers expert guidance to a patient. Tax Identification Number: 45-3266802.
- Clinical Study Participation: The CCCS001 observational study provides scientific analysis at no charge to participants. While Cancer Commons guidance is free, costs for Drug Sensitivity Tests and treatments may be covered through insurance, compassionate use programs, or other pathways.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free Expert Guidance for All Patients |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
Cancer Commons product offering
Product offeringCore offering
Cancer Commons is a 501(c)(3) nonprofit that provides free, PhD-level personalized treatment guidance to advanced/metastatic cancer patients who have exhausted standard-of-care options. Its core service pairs oncology nurses and clinical scientists who analyze tumor molecular profiles to recommend off-guideline FDA-approved drugs and clinical trials, delivered as a Scientific Evidence Report to the patient's own oncologist. The CCCS001 N-of-1 observational clinical study is the flagship research initiative supporting this guidance.
Product overview
Cancer Commons offers a unified service portfolio centered on Expert Guidance as the core offering—a personalized cancer treatment navigation service staffed by oncology nurses and PhD-level clinical scientists who analyze patient profiles to recommend actionable treatment plans. The CCCS001 Clinical Study (NCT07343024) is the flagship research initiative, an N-of-1 observational study that pairs patients with diagnostic testing (genomic profiling and drug sensitivity tests) to identify FDA-approved off-guideline treatment options. The study produces a Scientific Evidence Report as a key deliverable. Supporting offerings include Patient Stories (documented case studies) and Research News (expert-curated cancer research content). All services are provided free of charge to patients, funded through philanthropy.
Differentiator
Problem solved
Functional benefit
Products and services
- Expert Guidance Personalized cancer treatment navigation service that combines oncology nurses and PhD-level clinical scientists to analyze each patient's unique tumor molecular profile and treatment history, producing customized action plans for advanced cancer patients who have exhausted standard treatment options. The service identifies precision treatment matches, off-guideline FDA-approved drugs, clinical trial opportunities, and strategic treatment sequencing. All guidance is provided free to patients.
- CCCS001 Clinical Study N-of-1 Observational Clinical Study (NCT07343024) that uses advanced diagnostic tests including genomic profiling and Drug Sensitivity Tests to identify FDA-approved off-guideline drugs for advanced cancer patients. The site-less study enables participation through any oncologist nationwide with no travel required and produces a Scientific Evidence Report identifying promising treatment options.
- Scientific Evidence Report
Quantifiable outcome
- 10,000+ patients helped at no cost
- +3 more outcomes
Companies that use Cancer Commons
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles4 records
Cancer Commons technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Cancer Commons partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- xCurescorexCures is listed as a partner organization. Cancer Commons collaborates with xCures on initiatives that may benefit patients. Mika Newton, CEO of xCures, serves as a Distinguished Advisor to Cancer Commons.
- TempuscoreTempus is listed as a partner organization. Tempus provides genomic testing services that may be used by Cancer Commons patients for molecular profiling.
- H8 CancerminorH8 Cancer is listed as a partner organization supporting Cancer Commons mission.
- Pancreatic Cancer Action Network (Pancan)corePancreatic Cancer Action Network is listed as a partner organization, providing referral channel for pancreatic cancer patients seeking additional treatment options.
- Musella Foundation for Brain Tumor Research & InformationcoreThe Musella Foundation operates a patient navigation program in partnership with Cancer Commons and Head For The Cure. Al Musella, DPM serves as a Distinguished Advisor to Cancer Commons. The foundation supports brain tumor research and patient information.
- Poetic (POETIC Phase 1)minorPOETIC (Precision Oncology for Emerging Tumors Early-phase Immunotherapy Consortium) is listed as a partner organization.
- TraveracoreTravera provides cancer therapy selection tests that Cancer Commons utilizes. CEO Clifford Reid, PhD formerly co-founded Travera and serves as current CEO of Cancer Commons.
- Brain Cancer Support and Solutions Alliance (BCSSA)minorBCSSA has launched a dedicated nurse navigator program in partnership with Cancer Commons to provide comprehensive patient and caregiver assistance for brain cancer patients.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Cancer Commons competitors and assessment
Company assessmentDirect peers
- xCures: xCures is an AI-driven precision oncology platform that aggregates patient molecular and outcomes data to recommend individualized treatments for advanced cancer patients. It is directly comparable to Cancer Commons as both deliver off-guideline and clinical-trial treatment recommendations using patient data, and xCures is even listed as a Cancer Commons partner with its CEO serving as a Distinguished Advisor.
- Perthera: Perthera provides AI-enabled precision oncology treatment recommendations and molecular tumor board reviews for advanced cancer patients. It is a direct peer to Cancer Commons in matching off-guideline therapies and trials to molecular profiles, with a similar focus on patients who have exhausted standard options.
- Massive Bio: Massive Bio uses AI to match cancer patients with clinical trials and precision treatments. It is closely comparable to Cancer Commons' clinical trial exploration and treatment-matching services for advanced cancer patients, with a similar provider- and patient-facing workflow.
Broad incumbents
- Tempus: Tempus is a large precision medicine company offering genomic sequencing, AI-enabled clinical decision support, and clinical trial matching across oncology. It is a Cancer Commons partner for genomic testing and broadly comparable as a precision oncology intelligence platform, though it operates at much greater scale across many disease areas.
- Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling of tumors to inform treatment selection and clinical trial enrollment in oncology. It overlaps with Cancer Commons' molecular profiling and treatment-matching work, but operates at population scale as part of a broader diagnostics and pharma-services portfolio.
- Guardant Health: Guardant Health specializes in liquid biopsy and genomic profiling for advanced cancer, supporting therapy selection and disease monitoring. It is comparable to Cancer Commons in the oncology molecular diagnostics and treatment-matching domain, but with a much broader commercial footprint and FDA-approved tests.
- Caris Life Sciences: Caris offers molecular profiling (DNA, RNA, protein) and AI-driven precision oncology solutions to match patients with therapies and trials. It overlaps with Cancer Commons on tumor profiling and treatment recommendations, but operates as a full-service commercial diagnostics company serving oncologists across the US and internationally.
Emerging players
- Mendel.ai: Mendel.ai applies large language models to structured and unstructured clinical data to match oncology patients to clinical trials. It overlaps with Cancer Commons' clinical trial exploration service but focuses specifically on automated trial matching rather than full treatment recommendation.
- Deep 6 AI: Deep 6 AI uses AI to mine EHR data for clinical trial recruitment and cohort identification across therapeutic areas including oncology. It is thematically comparable to Cancer Commons' clinical trial matching capability, though Deep 6 primarily sells to sponsors and health systems rather than directly to patients.
Others
- Travera: Travera provides a drug sensitivity test that measures cancer cell responses to approved drugs. It is a Cancer Commons technology partner and directly comparable on the diagnostic side of Cancer Commons' CCCS001 study, though Travera operates as an upstream testing vendor rather than a full navigation service.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Cancer Commons social profiles
Digital presenceCancer Commons compliance and trust
Trust signalCompliance1 record
Cancer Commons financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cancer Commons leadership team
Management profileNumber of profiles
Profiles9 records
Cancer Commons funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cancer Commons M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cancer Commons
What does Cancer Commons do?
Cancer Commons is a 501(c)(3) nonprofit that provides free, PhD-level personalized treatment guidance to advanced/metastatic cancer patients who have exhausted standard-of-care options. Its core service pairs oncology nurses and clinical scientists who analyze tumor molecular profiles to recommend off-guideline FDA-approved drugs and clinical trials, delivered as a Scientific Evidence Report to the patient's own oncologist. The CCCS001 N-of-1 observational clinical study is the flagship research initiative supporting this guidance.
Is Cancer Commons a public or private company?
Cancer Commons is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Cancer Commons founded?
Cancer Commons was founded in 2011. It employs 11 to 50 people.
Where is Cancer Commons based?
Cancer Commons is headquartered in Palo Alto, United States, in the North America region.
How does Cancer Commons make money?
Two revenue lines are on record. Philanthropic Donations are the primary driver. The others are clinical Study Participation.
Who are Cancer Commons's main competitors?
Direct peers on record are xCures, Perthera and Massive Bio. Broad incumbents are Tempus, Foundation Medicine, Guardant Health and Caris Life Sciences. Emerging players are Mendel.ai and Deep 6 AI. Travera is listed as an others.
Does Cancer Commons have an API?
No public API is recorded for Cancer Commons.
What industry is Cancer Commons in?
Cancer Commons's product category is Oncology Patient Navigation Services. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 5417 and its SIC code is 8090.